Biogen Idec Inc (BIIB): Biogen Idec Product Pipeline Will Propel It Higher Seeking Alpha Thinking in terms of 2015 and later, by then we should also see [assuming FDA approval] revenue from Daclizumab for MS. Daclizumab is already approved to prevent the rejection of transplanted organs. Good data from a Phase 2 trial was announced in ... |
